Holen Sie sich die Stockscreener-App
3.29
1.36%
-0.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Altimmune Inc Aktie (ALT) Neueste Nachrichten
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases - Insider Monkey
Altimmune a new buy at Truist on pemvidutide promise - MSN
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
Altimmune, Inc. (ALT) gains analyst support as pemvidutide advances - MSN
Altimmune outlines 1,800-patient phase III MASH trial and signals cash runway into 2028 as pemvidutide advances - MSN
Growth Value: Can Altimmune Inc stock outperform in a bear marketWeekly Market Report & Consistent Income Trade Recommendations - baoquankhu1.vn
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX) - Seeking Alpha
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Truist initiates Altimmune stock coverage with buy rating on drug potential - Investing.com Australia
Altimmune (ALT) Gains Buy Rating with Promising MASH Treatment - GuruFocus
Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial - MarketBeat
What is HC Wainwright's Estimate for Altimmune Q1 Earnings? - MarketBeat
Altimmune (FRA:3G0) NonCurrent Deferred Revenue : €0.14 Mil (As of Dec. 2025) - GuruFocus
H.C. Wainwright raises Altimmune stock price target on MASH focus By Investing.com - Investing.com Australia
H.C. Wainwright raises Altimmune stock price target on MASH focus - Investing.com
HC Wainwright Forecasts Altimmune's Q4 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (ALT) 2026 proxy details share and ESPP increases - Stock Titan
Altimmune (NASDAQ:ALT) Price Target Raised to $25.00 at HC Wainwright - MarketBeat
Altimmune (ALT) Sees Price Target Raised by HC Wainwright & Co. to $25 | ALT Stock News - GuruFocus
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
3 Explosive Stocks With High Short Interest - AOL.com
Altimmune: The High Cost Of Going Solo (Rating Downgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune at Barclays Conference: Advancing Pemvidutide’s Potential By Investing.com - Investing.com Canada
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat - MarketBeat
Aug Final Week: Is Altimmune Inc stock a value trap2026 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn
ALT (Altimmune) NonCurrent Deferred Revenue : $0.16 Mil (As of Dec. 2025) - GuruFocus
Altimmune (MEX:ALT1) NonCurrent Deferred Revenue : MXN2.88 Mil (As of Dec. 2025) - GuruFocus
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up - MarketBeat
Altimmune at Leerink Conference: Strategic Advances in MASH Treatment By Investing.com - Investing.com Canada
Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference - MarketBeat
Altimmune at The Citizens Life Sciences Conference: Strategic Insights on Pemvidutide - Investing.com
ALT: Pemvidutide advances to phase 3, targeting MASH with strong efficacy and best-in-class tolerability - TradingView
Fireside chat set for Leerink Global Healthcare Conference, Altimmune announces - Traders Union
Altimmune Bets Big on PEMB as Phase III Nears - TipRanks
Altimmune to start late-stage trial for MASH candidate this year - MSN
Altimmune CFO Weaver buys $17,700 in shares By Investing.com - Investing.com Australia
Altimmune joins Citizens Life Sciences Conference for fireside chat in Miami Beach - Traders Union
Altimmune CEO Durso buys $70,790 in shares By Investing.com - Investing.com India
Altimmune CEO Durso buys $70,790 in shares - Investing.com Australia
Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock - MarketBeat
Altimmune Inc (ALT) CEO Jerome Durso Increases Stake with Recent Insider Purchase - GuruFocus
Altimmune CFO Weaver buys $17,700 in shares - Investing.com
Altimmune (NASDAQ: ALT) CFO buys 5,000 shares in open market - Stock Titan
Altimmune (NASDAQ: ALT) CEO buys 20,000 shares in open market - Stock Titan
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):